Want to see YI full AI Analyst Report?
YI Stock Chart & Stats
$2.85
-$0.01(-2.07%)
At close: 4:00 PM EST
$2.85
-$0.01(-2.07%)
Day’s Range― - ―
52-Week Range$2.48 - $11.17
Previous CloseN/A
Volume1.06M
Average Volume (3M)22.80K
Market Cap
$36.72M
Enterprise Value$251.30M
Total Cash (Recent Filing)$53.09M
Total Debt (Recent Filing)$41.16M
Price to Earnings (P/E)―
Beta0.64
Next Earnings
Aug 20, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-9.76
Shares Outstanding5,196,964
10 Day Avg. Volume15,490
30 Day Avg. Volume22,804
Financial Highlights & Ratios
PEG Ratio1.81
Price to Book (P/B)-0.22
Price to Sales (P/S)0.01
P/FCF Ratio1.36
Enterprise Value/Market Cap6.84
Enterprise Value/Revenue0.02
Enterprise Value/Gross Profit0.39
Enterprise Value/Ebitda-14.97
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)$17.20B
Bulls Say, Bears Say
Bulls Say
Asset-light Shift To Higher-margin Platform ServicesMoving to an asset-light, warehouse-partnership model and growing marketplace and promotional service revenue represents a structural business-model shift. Platform and marketplace economics can scale with lower working-capital needs, supporting sustainably higher gross margins and recurring service revenue.
Improved Cost Structure And Fulfillment EfficiencyA durable reduction in fulfillment expenses and improved cost share indicates operational leverage from the new fulfillment/partnership model. Lower logistics cost as a structural advantage helps protect margins and competitive pricing versus peers over the medium term.
Reduced Absolute Debt Versus Prior YearsLower absolute debt levels versus earlier periods reduce near-term refinancing pressure and interest burden. Coupled with an asset-light model, this improves financial optionality and reduces solvency stress, supporting longer-term strategic investments if cash generation stabilizes.
Bears Say
Consistently Negative Stockholders' EquityPersistent negative equity is a structural weakness that limits borrowing capacity, increases refinancing risk, and constrains strategic flexibility. It heightens solvency concerns and can force dilutive financing or asset sales to shore up capital over the medium term.
TTM Negative Operating And Free Cash FlowA reversion to sizable negative operating and free cash flow suggests the business cannot consistently self-fund operations or growth. Persistent cash burn increases reliance on external financing, raising execution and liquidity risk during adverse market conditions.
Choppy Revenue Trend And Very Thin Gross MarginsDeclining, inconsistent top-line coupled with single-digit gross margins limits the company's ability to absorb cost inflation or invest in growth. Thin product margins mean profitability hinges on scale or higher-margin services; without steady revenue, margin gains may be fragile.
111 News
YI FAQ
What was 111 Inc’s price range in the past 12 months?
111 Inc lowest stock price was $2.48 and its highest was $11.17 in the past 12 months.
What is 111 Inc’s market cap?
111 Inc’s market cap is $36.72M.
When is 111 Inc’s upcoming earnings report date?
111 Inc’s upcoming earnings report date is Aug 20, 2026 which is in 41 days.
How were 111 Inc’s earnings last quarter?
Currently, no data Available
Is 111 Inc overvalued?
According to Wall Street analysts 111 Inc’s price is currently Overvalued.
Does 111 Inc pay dividends?
111 Inc does not currently pay dividends.
What is 111 Inc’s EPS estimate?
111 Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does 111 Inc have?
111 Inc has 5,196,964 shares outstanding.
What happened to 111 Inc’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of 111 Inc?
Currently, no hedge funds are holding shares in YI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
111 Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Hedge Fund Trend
Decreased
By 90.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $300.8K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
-44.24%
12-Months-Change
Fundamentals
Return on Equity
8.26%
Trailing 12-Months
Asset Growth
-22.12%
Trailing 12-Months
Company Description
111 Inc
Based in Shanghai, People's Republic of China, 111, Inc. (established in 2010 and formerly known as New Peak Group until April 2018) is a prominent entity in the Chinese healthcare sector, operating a comprehensive online-to-offline (O2O) ecosystem. Its operations are structured across both business-to-business (B2B) and business-to-consumer (B2C) channels. The company facilitates the sale of a wide array of medical and wellness products, reaching customers through its online retail channels as well as wholesale and retail pharmacy networks. This extensive product catalog encompasses prescription medications, over-the-counter drugs (both Western and traditional Chinese), dietary supplements like vitamins, optical products such as contact lenses, various medical supplies and devices (e.g., bandages, thermometers), personal care items (including skincare, birth control, and sexual wellness products), and infant care essentials. Beyond product sales, 111, Inc. provides value-added services to consumers, such as online consultation and electronic prescription fulfillment. For its business partners, the company manages an online marketplace enabling third-party vendors to directly supply pharmacies. It further supports its "1 Pharmacy" clients – comprising pharmacies and wholesalers – with online loan application services, alongside offering data and supply chain integration solutions. Its operational scope also extends to critical back-end functions, including warehousing, logistics management, procurement, research and development, consulting, as well as software development and IT support. As of December 31, 2021, its physical footprint included 14 retail pharmacies operating under the "Yi Hao Pharmacy" brand across several key regions: Guangzhou, Tianjin, Kunshan, Chongqing, and Wuhan. The company caters to a diverse clientele, encompassing individual consumers, pharmacies, pharmaceutical manufacturers and distributors, medical practitioners, and insurance providers.
Technical Analysis
Rockwell Med
―
Dyadic International
―
Rein Therapeutics
―
Elutia
―
Neuphoria Therapeutics
―
Ownership Overview
46.78% Insiders
0.05% Mutual Funds
0.08% Other Institutional Investors
53.09% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---











